Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADXS Ayala Pharmaceuticals	$0.05	$0.07	$0.02 ▼ $0.78	$2.26M	1.17	4,709 shs	77 shs
CANF Can-Fite BioPharma	$0.66 +3.5%	$0.92	$0.63 ▼ $3.12	$2.33M	1.02	210,950 shs	347,956 shs
PLXP PLx Pharma		$0.00	$0.02 ▼ $0.04	$603K	3.79	12.96 million shs	3,000 shs
UPC Universe Pharmaceuticals	$3.50 +2.2%	$3.75	$2.51 ▼ $2,100.00	$1.97M	1.43	269,379 shs	19,265 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADXS Ayala Pharmaceuticals	0.00%	+3.92%	+59.16%	+41.33%	+165.00%
CANF Can-Fite BioPharma	-3.85%	-3.86%	-38.70%	-38.75%	-73.84%
PLXP PLx Pharma	0.00%	0.00%	0.00%	0.00%	0.00%
UPC Universe Pharmaceuticals	0.00%	-3.53%	+4.59%	-38.71%	-99.85%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADXS Ayala Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CANF Can-Fite BioPharma	1.9766 of 5 stars	3.5	2.0	0.0	0.0	1.1	0.0	1.3
PLXP PLx Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
UPC Universe Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADXS Ayala Pharmaceuticals	0.00	N/A	N/A	N/A
CANF Can-Fite BioPharma	3.00	Buy	$14.00	2,030.90% Upside
PLXP PLx Pharma	0.00	N/A	N/A	N/A
UPC Universe Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest PLXP, CANF, ADXS, and UPC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
7/29/2025	CANF Can-Fite BioPharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00

(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADXS Ayala Pharmaceuticals	$3.24M	0.70	N/A	N/A	($2.06) per share	-0.03
CANF Can-Fite BioPharma	$674K	3.45	N/A	N/A	$1.76 per share	0.37
PLXP PLx Pharma	$4.54M	0.00	N/A	N/A	$1.30 per share	0.00
UPC Universe Pharmaceuticals	$19.29M	0.10	N/A	N/A	$163.50 per share	0.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADXS Ayala Pharmaceuticals	-$48.07M	-$7.98	N/A	∞	N/A	N/A	N/A	N/A	N/A
CANF Can-Fite BioPharma	-$7.63M	-$1.79	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PLXP PLx Pharma	-$46.13M	-$1.85	N/A	N/A	N/A	-606.91%	-291.11%	-119.43%	N/A
UPC Universe Pharmaceuticals	-$6.16M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADXS Ayala Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CANF Can-Fite BioPharma	N/A	N/A	N/A	N/A	N/A
PLXP PLx Pharma	N/A	N/A	N/A	N/A	N/A
UPC Universe Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADXS Ayala Pharmaceuticals	N/A	N/A	N/A
CANF Can-Fite BioPharma	N/A	2.93	N/A
PLXP PLx Pharma	N/A	4.79	4.28
UPC Universe Pharmaceuticals	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADXS Ayala Pharmaceuticals	7.18%
CANF Can-Fite BioPharma	21.00%
PLXP PLx Pharma	21.19%
UPC Universe Pharmaceuticals	0.18%

Insider Ownership

Company	Insider Ownership
ADXS Ayala Pharmaceuticals	0.63%
CANF Can-Fite BioPharma	0.80%
PLXP PLx Pharma	8.95%
UPC Universe Pharmaceuticals	57.38%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADXS Ayala Pharmaceuticals	20	42.63 million	42.36 million	Not Optionable
CANF Can-Fite BioPharma	8	3.54 million	N/A	Not Optionable
PLXP PLx Pharma	16	29.14 million	26.53 million	Not Optionable
UPC Universe Pharmaceuticals	220	563,000	731,000	Not Optionable

PLXP, CANF, ADXS, and UPC Headlines

Recent News About These Companies

Universe Pharmaceuticals Inc. (UPC) Stock Price Today - WSJ

August 7, 2025 | wsj.com

Pharma Playbook: What Practitioners Can Learn from Early UPC Litigation

May 14, 2025 | ipwatchdog.comI

Universe Pharmaceuticals Reports Full Year 2024 Earnings

May 3, 2025 | finance.yahoo.com

Universe Pharmaceuticals INC Announces Share Consolidation Effective March 24, 2025

March 20, 2025 | quiverquant.comQ

Universe Pharmaceuticals INC Announces Share Consolidation

March 20, 2025 | gurufocus.com

Universe Pharmaceuticals INC Announces Share Consolidation

March 20, 2025 | investing.com

Universe Pharmaceuticals INC Announces Share Consolidation

March 20, 2025 | globenewswire.com

Universe Pharmaceuticals Approves Share Consolidation at Extraordinary Meeting

March 11, 2025 | tipranks.com

Universe Pharmaceuticals INC Faces Potential Delisting from Nasdaq Due to Delinquent Annual Report Filing

February 25, 2025 | quiverquant.comQ

Universe Pharmaceuticals INC Receives Staff Determination Notice from Nasdaq Related to Delayed Annual Report

February 25, 2025 | globenewswire.com

Universe Pharmaceuticals proposes revised share consolidation

February 11, 2025 | msn.com

Universe Pharmaceuticals (NASDAQ:UPC) Stock, Short Interest Report

February 10, 2025 | benzinga.com

Universe Pharmaceuticals INC.: Universe Pharmaceuticals INC Receives Nasdaq Delisting Notice Subject to Hearing Request

February 6, 2025 | finanznachrichten.de

UPC’s Unexpected Plunge: What’s Next?

February 5, 2025 | bovnews.comB

Universe Pharmaceuticals gets Nasdaq delisting notice

February 4, 2025 | markets.businessinsider.com

Universe Pharmaceuticals INC Faces Nasdaq Delisting Due to Low Share Price

February 3, 2025 | quiverquant.comQ

Universe Pharmaceuticals INC Receives Nasdaq Delisting Notice Subject to Hearing Request

February 3, 2025 | globenewswire.com

Universe Pharmaceuticals announces shareholder meeting

January 30, 2025 | msn.com

Universe Pharmaceuticals stock hits 52-week low at $0.48 amid steep decline

January 29, 2025 | msn.com

Universe Pharmaceuticals Inc (UPC) Stock: A Deeper Look at Its True Potential

December 29, 2024 | bovnews.comB

New MarketBeat Followers Over Time

PLXP, CANF, ADXS, and UPC Company Descriptions

Ayala Pharmaceuticals NASDAQ:ADXS

$0.05 0.00 (0.00%)

As of 08/19/2025

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

Can-Fite BioPharma NYSE:CANF

$0.66 +0.02 (+3.55%)

Closing price 03:56 PM Eastern

Extended Trading

$0.66 +0.01 (+0.91%)

As of 04:23 PM Eastern

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

PLx Pharma NASDAQ:PLXP

PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. It offers PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Sparta, NJ.

Universe Pharmaceuticals NYSE:UPC

$3.50 +0.08 (+2.19%)

Closing price 03:50 PM Eastern

Extended Trading

$3.52 +0.02 (+0.69%)

As of 04:01 PM Eastern

Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party products, including biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was founded in 1998 and is based in Ji'An, China. Universe Pharmaceuticals INC operates as a subsidiary of Sununion Holding Group Limited.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time